There is an increased number of lawsuits filed against the manufacturers of both Onglyza and Kombiglyze XR. As of October 2015, there have been 749 pending cases, with additional lawsuits expected to be filed in federal court.
Saxagliptin, the active ingredient in Onglyza and Kombiglyze, is a DPP-4 inhibitor, which is an enzyme that naturally occurs in the body. DDP-4 works to break down an incretin hormone called glucagon-like peptide-1 (GLP-1) after it is released into the blood, and signals the pancreas to make insulin. Patients with diabetes have reduced secretion of GLP-1, resulting in less insulin produced...Read More
Manufacturers AstraZeneca, and partners Bristol-Myers Squibb, have faced numerous lawsuits against them for their drugs Onglyza and Kombiglyze. Claims made against these companies include the fact that they did not disclose of the more serious side effects of their medication, including pancreatitis, pancreatic cancer, thyroid cancer, and heart failure.
In October 2015, one...Read More
Many who have filed lawsuits against AstraZeneca and Bristol-Myers Squibb have claimed that the manufacturers “overpromoted and underwarned” the drugs. They argue that had patients and doctors...Read More